Improving effect of ethyl eicosapentanoate on statin-induced rhabdomyolysis in Eisai hyperbilirubinemic rats

Biochemical and Biophysical Research Communications

Volumn 340, Issue 1, 2006, Pages 215-220

  Naba, Hiroyasu ^a   Kakinuma, Chihaya ^a   Ohnishi, Shuhei ^a   Ogihara, Takuo ^a  

^a MOCHIDA PHARMACEUTICAL CO   (Japan)

Author keywords

EHBR; EPA E; Ethyl eicosapentanoate; Myopathy; Pravastatin; Rhabdomyolysis; Statin

Indexed keywords

BILIRUBIN; CREATINE KINASE; ICOSAPENTAENOIC ACID ETHYL ESTER; MYOGLOBIN; PRAVASTATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG EFFECT; HYPERBILIRUBINEMIA; INCIDENCE; MALE; MUSCLE ATROPHY; NONHUMAN; PRIORITY JOURNAL; RAT; RAT STRAIN; RHABDOMYOLYSIS; SKELETAL MUSCLE;

ANIMALS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; EICOSAPENTAENOIC ACID; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERBILIRUBINEMIA; MUSCLE, SKELETAL; PLATELET AGGREGATION INHIBITORS; PRAVASTATIN; RATS; RHABDOMYOLYSIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ANIMALIA;

EID: 29244436839     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2005.11.179     Document Type: Article

References (34)

1. J. Shepherd, S.M. Cobbe, I. Ford, C.G. Isles, A.R. Lorimer, P.W. MacFarlane, J.H. McKillop, and C.J. Packard Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland coronary prevention study group New Engl. J. Med. 333 1995 1301 1307
2. S.M. Grundy HMG-CoA reductase inhibitors for treatment of hypercholesterolemia New Engl. J. Med. 319 1988 24 33
3. E.S. Istvan, and J. Deisenhofer Structural mechanism for statin inhibition of HMG-CoA reductase Science 292 2001 1160 1164
4. M.S. Brown, and J.L. Goldstein A receptor-mediated pathway for cholesterol homeostasis Science 232 1986 34 47
5. J.I. Harris, J.R. Hibbeln, R.H. Mackey, and M.F. Muldoon Statin treatment alters serum n-3 and n-6 fatty acids in hypercholesterolemic patients Prostaglandins Leukot. Essent. Fatty Acids 71 2004 263 269
6. M.A. Omar, J.P. Wilson, and T.S. Cox Rhabdomyolysis and HMG-CoA reductase inhibitors Ann. Pharmacother. 35 2001 1096 1107
7. A.S. Wierzbicki, D.P. Mikhailidis, R. Wray, M. Schacter, R. Cramb, W.G. Simpson, and C.B. Byrne Statin-fibrate combination: therapy for hyperlipidemia: a review Curr. Med. Res. Opin. 19 2003 155 168
8. K. Mizuguchi, T. Yano, M. Kojima, Y. Tanaka, M. Ishibashi, A. Masada, M. Sato, M. Mizota, K. Fukutake, and Y. Saito Hypolipidemic effect of ethyl all-cis-5,8,11,14,17-eicosapentaenoate (EPA-E) in rats Jpn. J. Pharmacol. 59 1992 307 312
9. K. Mizuguchi, T. Yano, Y. Tanaka, M. Ishibashi, A. Masada, M. Mizota, K. Fukutake, and Y. Saito Mechanism of the lipid-lowering effect of ethyl all-cis-5,8,11,14,17-icosapentaenoate Eur. J. Pharmacol. 231 1993 121 127
10. M. Sato, Y. Katsuki, K. Fukuhara, H. Kawano, M. Mizota, Y. Hamada, and Y. Kunihiro Effects of highly purified ethyl all-cis-5,8,11,14,17-icosapentaenoate (EPA-E) on rabbit platelets Biol. Pharm. Bull 16 1993 362 367
11. K. Mizuguchi, T. Yano, M. Ishibashi, A. Masada, M. Mizota, and Y. Saito Ethyl all-cis-5,8,11,14,17-icosapentaenoate modifies the biochemical properties of rat very low-density lipoprotein Eur. J. Pharmacol. 235 1993 221 227
12. M. Sato, Y. Katsuki, H. Kanehiro, M. Iimura, Y. Akada, M. Mizota, and Y. Kunihiro Effects of ethyl all-cis-5,8,11,14,17-icosapentaenoate on the physical properties of arterial walls in high cholesterol diet-fed rabbits J. Cardiovasc. Pharmacol. 22 1993 1 9
13. T. Yano, H. Kawano, M. Yamashita, K. Mizuguchi, H. Mochizuki, and T. Iwamoto Effects of ethyl-all-cis-5,8,11,14,17-icosapentaenoate (EPA-E), pravastatin and their combination on serum lipids and intimal thickening of cuff-sheathed carotid artery in rabbits Life Sci. 61 1997 2007 2015
14. S. Pierno, A. De Luca, D. Tricarico, A. Roselli, F. Natuzzi, E. Ferrannini, M. Laico, and D.C. Camerino Potential risk of myopathy by HMG-CoA reductase inhibitors: a comparison of pravastatin and simvastatin effects on membrane electrical properties of rat skeletal muscle fibers J. Pharmacol. Exp. Ther. 275 1995 1490 1496
15. S. Pierno, A. De Luca, A. Liantonio, C. Camerino, and D. Conte Camerino Effects of HMG-CoA reductase inhibitors on excitation-contraction coupling of rat skeletal muscle Eur. J. Pharmacol. 364 1999 43 48
16. P.F. Smith, R.S. Eydelloth, S.J. Grossman, R.J. Stubbs, M.S. Schwartz, J.I. Germershausen, K.P. Vyas, P.H. Kari, and J.S. MacDonald HMG-CoA reductase inhibitor-induced myopathy in the rat: cyclosporine A interaction and mechanism studies J. Pharmacol. Exp. Ther. 257 1991 1225 1235
17. H. Naba, C. Kuwayama, C. Kakinuma, S. Ohnishi, and T. Ogihara Eisai hyperbilirubinemic rat (EHBR) as an animal model affording high drug-exposure in toxicity studies on organic anions Drug. Metab. Pharmacokinet. 19 2004 339 351
18. K. Yamazaki, T. Mikami, S. Hosokawa, O. Tagaya, Y. Nozaki, A. Kawaguchi, H. Funami, H. Katoh, N. Yamamoto, and T. Wakabayashi A new mutant rat with hyperbilirubinuria (hyb) J. Hered. 86 1995 314 317
19. D. Keppler, J. Konig, and M. Buchler The canalicular multidrug resistance protein, cMRP/MRP2, a novel conjugate export pump expressed in the apical membrane of hepatocytes Adv. Enzyme Regul. 37 1997 321 333
20. K. Ito, H. Suzuki, T. Hirohashi, K. Kume, T. Shimizu, and Y. Sugiyama Molecular cloning of canalicular multispecific organic anion transporter defective in EHBR Am. J. Physiol. 272 1997 G16 G22
21. M. Yamazaki, K. Kobayashi, and Y. Sugiyama Primary active transport of pravastatin across the liver canalicular membrane in normal and mutant Eisai hyperbilirubinaemic rats Biopharm. Drug Dispos. 17 1996 645 659
22. Y. Adachi, Y. Okuyama, H. Miya, H. Matsusita, M. Kitano, T. Kamisako, and T. Yamamoto Pravastatin transport across the hepatocyte canalicular membrane requires both ATP and a transmembrane pH gradient J. Gastroenterol. Hepatol. 11 1996 580 585
23. M. Yamazaki, S. Akiyama, K. Ni'inuma, R. Nishigaki, and Y. Sugiyama Biliary excretion of pravastatin in rats: contribution of the excretion pathway mediated by canalicular multispecific organic anion transporter Drug Metab. Dispos. 25 1997 1123 1129
24. S. Fukumura, H. Takikawa, and M. Yamanaka Effects of organic anions and bile acid conjugates on biliary excretion of pravastatin in the rat Pharm. Res. 15 1998 72 76
25. S. Shintani, T. Shiigai, and H. Tsukagoshi Marked hypokalemic rhabdomyolysis with myoglobinuria due to diuretic treatment Eur. Neurol. 31 1991 396 398
26. S.M. Jamal, M.J. Eisenberg, and S. Christopoulos Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors Am. Heart J. 147 2004 956 965
27. K. Folkers, P. Langsjoen, R. Willis, P. Richardson, L.J. Xia, C.Q. Ye, and H. Tamagawa Lovastatin decreases coenzyme Q levels in humans Proc. Natl. Acad. Sci. USA 87 1990 8931 8934
28. G. De Pinieux, P. Chariot, M. Ammi-Said, F. Louarn, J.L. Lejonc, A. Astier, B. Jacotot, and R. Gherardi Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio Br. J. Clin. Pharmacol. 42 1996 333 337
29. C. Guijarro, L.M. Blanco-Colio, M. Ortego, C. Alonso, A. Ortiz, J.J. Plaza, C. Diaz, G. Hernandez, and J. Egido 3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture Circ. Res. 83 1998 490 500
30. H. Nakagawa, T. Mutoh, T. Kumano, and M. Kuriyama Tyrosine phosphorylation of the catalytic subunit p110 of phosphatidylinositol-3 kinase induced by HMG-CoA reductase inhibitor inhibits its kinase activity in L6 myoblasts FEBS Lett. 508 2001 53 56
31. S. Pierno, A. De Luca, D. Tricarico, E. Ferrannini, T. Conte, G. D'Alo, and D.C. Camerino Experimental evaluation of the effects of pravastatin on electrophysiological parameters of rat skeletal muscle Pharmacol. Toxicol. 71 1992 325 329
32. S. Bramow, P. Ott, F. Thomsen Nielsen, K. Bangert, N. Tygstrup, and K. Dalhoff Cholestasis and regulation of genes related to drug metabolism and biliary transport in rat liver following treatment with cyclosporine A and sirolimus (Rapamycin) Pharmacol. Toxicol. 89 2001 133 139
33. Y. Nishizato, I. Ieiri, H. Suzuki, M. Kimura, K. Kawabata, T. Hirota, H. Takane, S. Irie, H. Kusuhara, Y. Urasaki, A. Urae, S. Higuchi, K. Otsubo, and Y. Sugiyama Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics Clin. Pharmacol. Ther. 73 2003 554 565
34. K. Morimoto, T. Oishi, S. Ueda, M. Ueda, M. Hosokawa, and K. Chiba A novel variant allele of OATP-C (SLCO1B1) found in a Japanese patient with pravastatin-induced myopathy Drug Metab. Pharmacokinet. 19 2004 453 455